Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Kodiak Sciences Inc., reported business highlights and financial results for the quarter and year ended December 31, 2023.
Uncategorized
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
DarioHealth Corp., a leader in the global digital health market, reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results Read More »
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
Tigermed Reports Full Year 2023 Results
Hangzhou Tigermed Consulting Co., Ltd., a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023.
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Stoke Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering Read More »
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference
Vicore Pharma Holding AB announced multiple presentations at the 2024 American Thoracic Society International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis.
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
Virion Therapeutics, LLC announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong, M.D., from the Chinese University of Hong Kong, as a late breaker oral presentation at the 33rd Annual Meeting of APASL in Kyoto, Japan.
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Akebia Therapeutics®, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo® Tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
Identifican dos de los bloques más antiguos con los que se formó nuestra galaxia
La historia temprana de nuestra galaxia, la Vía Láctea, engloba la unión de galaxias más pequeñas en estructuras cada vez más grandes, hasta llegar al estado actual. Unos científicos han logrado identificar lo que parece ser dos de los primeros bloque …
Identifican dos de los bloques más antiguos con los que se formó nuestra galaxia Read More »
Dotar de sentido común a los robots domésticos
En un futuro no muy lejano, habrá robots que harán muchos más trabajos domésticos que barrer, aspirar y fregar. Sin embargo, su mayor actividad en el hogar aumentará las posibilidades de que la presencia de humanos a su alrededor entorpezca su labor. Un hu …